Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 2Urinary Bladder Neoplasms 1Precancerous Conditions 1Polyps 1Neoplastic Syndromes, Hereditary 1Mouth Neoplasms 1Keratosis, Actinic 1Intestinal Neoplasms 1Intestinal Diseases 1Genetic Diseases, Inborn 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Duodenal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Adenomatous Polyps 1Adenomatous Polyposis Coli 1Adenoma 1

Interventions

Gemcitabine 6Carboplatin 3valrubicin 2Cisplatin 2vinflunine 1toripalimab 1pertuzumab 1disitamab vedotin 1cabazitaxel 1apaziquone 1XRP6258 1Watchful Waiting 1Vinblastine 1Trastuzumab 1Transurethral Resection of Bladder 1Tranexamic Acid 1Saline Solution 1RC48 antibody 1Oncolytic Virotherapy 1Mitomycin 1Methotrexate 1Magnetic Resonance Spectroscopy 1Lapatinib 1Interferons 1Interferon-alpha 1Gabapentin 1Circulating Tumor DNA 1Celecoxib 1BCG Vaccine 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Urinary Bladder Neoplasms × Celecoxib × Clear all
NCT00006124 2013-02-13

Celecoxib in Treating Patients With Bladder Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
152 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡